News for Oxford Biomedica plc (OXB.L)

OXB has achieved full ownership of its US branch by acquiring the remaining 10% stake from Q32 Bio, bringing its total ownership to 100%. The decision to exerci

Oxford Biomedica (OXBDF) has announced the establishment of its Innovation and Technology Excellence Board (ITEB). This newly formed advisory board will guide t

Total Revenue: GBP128.8 million, a 44% increase over the previous year.Organic Revenue Growth: 81% in 2024.Client Orders: GBP186 million in 2024, a 35% increas

Apr 09, 2025 / 12:00PM GMTFrank Mathias - Oxford Biomedica PLC - Chief Executive Officer, Executive Director So good afternoon to everyone here in London and al

The following slide deck was published by Oxford Biomedica plc in conjunction with their 2024 Q4 earnings call.

Oxford Biomedica plc (OTCPK:OXBDF) Q4 2024 Earnings Conference Call April 9, 2025 8:00 AM ETCompany ParticipantsFrank Mathias - Chief Executive...

**media[536253]**

Revenue: GBP50.8 million, up 18% from GBP43.1 million in the same period last year.Organic Revenue Growth: 38% excluding the impact of the acquisition of OXB F

Sep 23, 2024 / 12:30PM GMTFrank Mathias - Oxford Biomedica PLC - Chief Executive Officer, Executive Director Good afternoon, everyone and good morning to those

Oxford Biomedica plc (OTCPK:OXBDF) Q2 2024 Earnings Conference Call September 23, 2024 8:00 AM ETCompany ParticipantsFrank Mathias - Chief Executive...

Interim Results for the Six Months Ended 30 June 2024

Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued execution of...

Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 September 2024: OXB (LSE:OXB),...

Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford...

Oxford Biomedica to host a free webinar showcasing its AAV expertise Oxford, UK - 27 August 2024: On Wednesday 11 September 2024, Oxford Biomedica, a...

Half Year Trading Update and Notice of Interim Results Full year 2024 revenue and medium-term financial guidance reiterated; underpinned by OXB’s growing...

Visiongain has published a new report entitled Retinal Gene Therapy Market Report 2024-2034: Forecasts by Approach (Gene Replacement, Gene Silencing, Gene...

The following is a round-up of earnings and trading updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News: ---------- Roadside Real Estate PLC -...

BEDFORD, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX) today announced that it declared a distribution to its common...